China’s First Long-Acting RSV Preventive Antibody Approved

TREE NEWS update: Simcere Pharmaceutical announced that its co-developed Class 1 biologic, culerviveimab injection (brand name Yingmule), has been approved by China’s National Medical Products Administration. It becomes the first domestically developed long-acting preventive monoclonal antibody for respiratory syncytial virus (RSV) in the country. The drug was developed in strategic partnership with Ruiyang (Shandong) Biopharmaceutical.